A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

ConclusionsThis study demonstrated high PK similarity between GB242 and its marketed reference infliximab in healthy subjects. Both treatments showed comparable safety and immunogenicity.Registration numberChiCTR-IPR-15007098
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research